43235/43239 Esophagogastroduodenoscopy to evaluate varices or portal hypertensive gastropathy
[90] In March 2026, the CHMP recommended granting a conditional marketing authorization for Kayshild (semaglutide), a GLP-1 receptor agonist for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, a serious disease where fat deposits accumulate in the liver causing inflammation
or BMI 27 kg/m with at least one indicator of increased cardiovascular risk (e.g., coronary heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference), or another obesity-related medical condition (e.g., sleep apnea)
Despite not being required by the drugs Risk Evaluation and Mitigation Strategy (REMS), regular liver enzyme monitoring is recommended [107]
Lastly, we have Glutathione, a strong antioxidant
Only one administration code applies per injection encounter based on the nature of the agent (therapeutic vs